- Home
- ZBIO
ZBIO
ZENAS BIOPHARMA INC
as 01-21-2025 4:00pm EST
Stocks
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.
| Founded: | 2019 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 339.3M | IPO Year: | 2024 |
| Target Price: | $31.75 | AVG Volume (30 days): | 371.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -41.59 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.50 - $26.25 | Next Earning Date: | 02-16-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest ZENAS BIOPHARMA INC News
ZBIO Breaking Stock News: Dive into ZBIO Ticker-Specific Updates for Smart Investing
TipRanks
a month ago
Zenas BioPharma initiated with a Buy at H.C. Wainwright
MT Newswires
a month ago
HC Wainwright Initiates Zenas BioPharma at Buy With $30 Price Target
TipRanks
a month ago
Zenas BioPharma price target lowered to $35 from $40 at Morgan Stanley
Argus Research
2 months ago
Daily – Vickers Top Buyers & Sellers for 12/05/2024
Argus Research
2 months ago
Daily – Vickers Top Buyers & Sellers for 11/21/2024
GlobeNewswire
2 months ago
Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
GlobeNewswire
2 months ago
Zenas BioPharma Completes Targeted Enrollment of the Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)
GlobeNewswire
2 months ago
Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences
Compare ZBIO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ZBIO ZENAS BIOPHARMA INC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.